{"id":77586,"date":"2024-03-12T15:28:52","date_gmt":"2024-03-12T20:28:52","guid":{"rendered":"https:\/\/equitynewsreport.com\/marla-beck-named-ceo-of-the-beauty-health-company\/"},"modified":"2024-03-12T15:28:52","modified_gmt":"2024-03-12T20:28:52","slug":"marla-beck-named-ceo-of-the-beauty-health-company","status":"publish","type":"post","link":"https:\/\/equitynewsreport.com\/h\/marla-beck-named-ceo-of-the-beauty-health-company\/","title":{"rendered":"Marla Beck named CEO of The Beauty Health Company"},"content":{"rendered":"
\n
\n\"Marla
\n\u00a9 Reuters. <\/span>
\n<\/i>\n<\/div>\n

LONG BEACH, Calif. – The Beauty Health Company (NASDAQ: SKIN), known for its Hydrafacial brand, has appointed Marla Beck as its President and Chief Executive Officer, a role she has filled on an interim basis since November 2023. Beck, who is also a member of the company’s Board of Directors, was confirmed unanimously by the Board to lead the company permanently.<\/p>\n

Beck’s leadership has been under evaluation since her appointment as interim CEO in November last year. Saunders, Chairman of the Board, expressed confidence in Beck’s capabilities, citing her performance and deep industry knowledge as key factors in the Board’s decision. He highlighted her proven track record in building brands that resonate with consumers and deliver value.<\/p>\n

As the founder and former CEO of Bluemercury, Beck has extensive experience in the beauty industry. She grew Bluemercury from its inception in 1999 to its acquisition by Macy’s (NYSE:) in 2015, where she continued to oversee the brand as an independent unit until 2021.<\/p>\n

Her entrepreneurial background is complemented by her earlier consulting work at McKinsey & Company, and her academic credentials include degrees from the University of California, Berkeley, Harvard Business School, and Harvard’s John F. Kennedy School of Government.<\/p>\n

In her statement, Beck expressed her belief in the growth potential of BeautyHealth and its flagship brand, Hydrafacial. She emphasized the company’s unique strengths and her commitment to driving growth and value for stakeholders through operational excellence and financial discipline.<\/p>\n

The Beauty Health Company positions itself as a pioneer in skin health, offering a range of treatments and services designed to cater to diverse skincare needs. Its portfolio includes the Hydrafacial hydradermabrasion, SkinStylus microneedling, and Keravive scalp health treatments.<\/p>\n

This announcement is based on a press release statement from The Beauty Health Company.<\/p>\n

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u00a9 Reuters. LONG BEACH, Calif. – The Beauty Health Company (NASDAQ: SKIN), known for its Hydrafacial brand, has appointed Marla Beck as its President and Chief Executive Officer, a role she has filled on an interim basis since November 2023. Beck, who is also a member of the company’s Board of Directors, was confirmed unanimously by the Board to lead the company permanently. Beck’s leadership has been under evaluation since her appointment as interim CEO in November last year. Saunders, Chairman of the Board, expressed confidence in Beck’s capabilities, citing her performance and deep industry knowledge as key factors in […]<\/p>\n","protected":false},"author":5,"featured_media":77587,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,49,50,3],"tags":[],"_links":{"self":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/posts\/77586"}],"collection":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/comments?post=77586"}],"version-history":[{"count":0,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/posts\/77586\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/media\/77587"}],"wp:attachment":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/media?parent=77586"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/categories?post=77586"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/tags?post=77586"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}